news

Japanese pharma market set for strong growth in 2019

45
SHARES

The report, published from CPhI Japan 2019, highlights the country as the second fastest growing mature market for solid dose drugs.

generics

Japan was also shown to be the second faster overall country for biologicals growth, finishing just behind the United States.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The findings represent a sizeable year-on-year improvement in outlook for pharma in Japan, with expected growth of solid dose formulations improving by more than 10 percent with generic drug classes highlighted as offering strong growth prospects.

Laura Murina, brand manager CPhI Japan said: “Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are now observing a dramatic increase in generics and biosimilars in the market.”

Japanese companies reported renewed confidence in the domestic market but more significantly, a larger number are also exploring exports than in previous years. In 2019, it’s expected that Japan’s largest pharma companies will gain 50 percent of their sales from overseas sales.

A resurgence in international trade is being driven by deregulation, which has helped accelerate approval pathways. Research and development (R&D) in Japan is also helping to drive the attractiveness of the nation’s medicine market, according to the report.

Nobuaki Nito, general manager UBM Japan, added: “What is most exciting, is that with international collaborations increasing, there are clearly now more partnering opportunities in the market than ever before.”

The report concludes that Japan has strong potential in pharma, with renewed opportunities for international contract service providers, generics and finished drug manufacturers as well as domestic manufacturers to become the local manufacturing arms of international firms.

Share via
Share via